Search the Newsreel

Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Halozyme Therapeutics CEO Helen Torley sold 20,000 shares of the company's stock for over $2 million, executed under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced her holdings by 2.54%. The company recently exceeded analyst estimates with strong quarterly earnings and revenue growth, …

Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8

Roth MKM has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its target price of $8. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Neumora Therapeutics (NMRA) insider plans new stock sale after $329K in recent trades

Neumora Therapeutics (NMRA) officer Daljit Singh Aurora has filed a Rule 144 notice for a planned sale of 61,918 shares of common stock on August 19, 2026, through a broker-assisted cashless sale after exercising employee stock options. This follows previous sales by Aurora in …

Ocular (OCUL) Latest Quarter: The EPS Result Is Above Expectation in the Latest Session; Shares Move 6.54% Up on the Day - Adjusted Earnings Analysis

PMV (PMVP) Latest Quarter: The Available Earnings Metric Delivers a Beat in the Latest Reading; Closing Move: The Stock Records a 3.23% Increase on the Day - Analyst Coverage Count

Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh

This article is a statement of changes in beneficial ownership of securities for Officer Aurora Daljit Singh at Neumora Therapeutics. It is identified as a Form 4 filing, which indicates a required disclosure of insider trading activity.

Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares

Jolanda Howe, SVP, Global Controller at Mirum Pharmaceuticals (MIRM), exercised 40,000 employee stock options at $6.27 per share and subsequently sold all 40,000 common shares at $100.00 per share on August 18, 2026. This transaction resulted in an approximate pre-tax spread of $3.75 million. …

Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current Update - Financial Health Score

Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain

Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?

Relay Therapeutics (RLAY) reported Q2 2026 results with revenue of US$0.35 million and a net loss of US$83.71 million. Despite recent share price recovery, the company's P/B ratio of 5.1x is higher than its peers and the broader biotech industry, suggesting it is overvalued. …

Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan

Structure Therapeutics' Chief Scientific Officer, Xichen Lin, reported insider activity on August 18, 2026, which included exercising options for 11,817 Ordinary Shares and converting them into 3,939 American Depositary Shares (ADSs). All 3,939 ADSs were subsequently sold in three tranches at weighted average prices …

Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares

Lexeo Therapeutics CEO Richard Nolan Townsend sold 3,345 shares of LXEO stock for $16,557.75 to cover tax-withholding obligations related to vested equity awards. This sale reduced his ownership by 0.89%, leaving him with 374,472 shares. Despite a quarterly loss and some analyst downgrades, LXEO …

Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares

Lexeo Therapeutics, Inc. (LXEO) CEO Richard Nolan Townsend sold 3,345 shares of common stock on August 18, 2026, at a weighted average price of $4.9512 per share. This sale was conducted to cover tax obligations arising from the release of restricted stock units (RSUs). …

Halozyme (NASDAQ: HALO) CEO sells tens of thousands of shares

Halozyme (NASDAQ: HALO) President and CEO Helen Torley exercised stock options and sold 60,000 common shares between August 17-19, 2026, under a pre-arranged Rule 10b5-1 trading plan. She exercised options at $18.41 per share and sold the shares in the high $90s to approximately …

Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN

Handelsbanken Fonder AB recently acquired 53,200 shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) valued at approximately $1.18 million, contributing to institutional investors owning 96.68% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $34.42, despite the company reporting a …

Eureka Group posts record all-age rental growth in FY26 results

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance1: Double-digit revenue growth and gross …

Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics CFO Louis Edward Tamayo sold 4,117 shares of LXEO stock for $20,214.47 to cover tax obligations, reducing his stake by 4.24% to 92,907 shares. The company's stock rose to $5.37 during mid-day trading despite missing quarterly EPS estimates, and institutional ownership stands …

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares of Stock

Major shareholder Group Walters purchased 4,335,000 shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock for $15.17 million, increasing their position by 32.09% to 17.84 million shares. This transaction occurred on August 14th, with the stock bought at an average price of $3.50 per share. Despite the …

An2 Therapeutics director Robin Readnour sells $212,701 in common stock By Investing.com

Robin Shane Readnour, a director at AN2 Therapeutics (ANTX), sold 35,402 shares of common stock for a total of $212,701 on August 17, 2026. These transactions, executed at an average price of $6.0082 per share, were conducted under Rule 10b5-1 trading plans. Despite the …

Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Jolanda Howe, SVP of Mirum Pharmaceuticals (NASDAQ:MIRM), sold 40,000 shares of the company's stock for $4 million on August 18th, reducing her stake by 96.91% to 1,274 shares. This sale follows several other transactions since June. The company's stock trades at $102.24 with a …

Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX

This article focuses on the total non-current assets of Definium Therapeutics, Inc. (NASDAQ: DFTX). It appears to be a financial data page from TradingView, displaying company information and navigational elements for financial analysis. The content indicates market data and reference data providers for the …

Enterprise value to EBITDA forward of Context Therapeutics Inc. – NASDAQ:CNTX

This article displays the Enterprise Value to EBITDA forward for Context Therapeutics Inc. (NASDAQ: CNTX). It provides basic financial information related to the company within the TradingView platform. The content is primarily a data point display from a financial charting service.

Structure (GPCR) Earnings Reading: EPS Comes in Below Forecast in the Current Update; Market Response: The Stock Gains 1.12% in the Latest Session - Analyst Coverage Count

We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate

BioCryst (BCRX) Quarterly Figures: Reported EPS Tops Expectations in the Latest Reading; Price Reaction: The Share Price Adds 3.81% at the Close - Earnings Growth Analysis

Beam (BEAM) Latest Quarter: EPS Falls Short of Its Estimate on the Day; Post-Earnings: The Stock Gains 9.41% in the Current Update - Revenue Inflection Point

If You Invested $100 In Marathon Petroleum Stock 15 Years Ago, You Would Have This Much Today

This article examines the hypothetical return on a $100 investment in Marathon Petroleum (NYSE: MPC) made 15 years ago. The investment would have grown to $2,013.68 today, reflecting an annualized return of 22.5%. Marathon Petroleum has outperformed the market by 9.08% annually over this …

TEVA Stock Quote Price and Forecast

Eureka Group Holdings Reports Revenue of $56.7M and Final Dividend of 0.73 Cents for FY2026

PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 2,813 Shares of Stock

PTC Therapeutics VP Mark Elliott Boulding sold 2,813 shares of the company's stock on August 17th for a total of $204,139.41, reducing his ownership by 2.60%. This sale was part of a pre-arranged Rule 10b5-1 trading plan and follows earlier sales in June and …

Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com

Sonoma Pharmaceuticals announced the cancellation of its adjourned special meeting of stockholders due to a lack of quorum, as not enough shareholders participated to meet the required threshold. The meeting was originally called to address matters detailed in a proxy statement from May 2026. …

Walters Group acquires $15.17 million in Zentalis Pharmaceuticals stock By Investing.com

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 3.3% in the afternoon session after the company agreed to acquire Alesta Therapeutics, a clinical-stage biotech company. According to a company press release, BioMarin will pay …

AARD Class Action Reminder - Robbins LLP Reminds Investors

Robbins LLP is reminding investors of a class action lawsuit against Aardvark Therapeutics, Inc. (NASDAQ: AARD) concerning its IPO in February 2025 and subsequent stock drop. The lawsuit alleges that Aardvark misled investors about the safety and efficacy of its lead drug candidate, ARD-101, …